Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism

Abstract

Get full access to this article

View all access options for this article.

References

Limongelli

Monda

Tramonte

, et al. Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. Int J Cardiol.. Epub ahead of print 4 July 2019. DOI: 10.1016/j.ijcard.2019.06.073.

Liu

Berger

, et al. Survival and prognostic factors in hypertrophic cardiomyopathy: A meta-analysis. Sci Rep 2017; 7: 11957.

Norrish

Cantarutti

Pissaridou

, et al. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. Eur J Prev Cardiol 2017; 24: 1220–1230.

Gragnano

Golia

Natale

, et al. Von Willebrand factor and cardiovascular disease: From a biochemical marker to an attractive therapeutic target. Curr Vasc Pharmacol 2017; 15: 404–415.

Ganguly

Alam

. Role of homocysteine in the development of cardiovascular disease. Nutr J 2015; 14: 6.

Spence

. Homocysteine lowering for stroke prevention: Unravelling the complexity of the evidence. Int J Stroke 2016; 11: 744–747.